雷珠单抗在新生血管性青光眼治疗中的有效性与安全性探究
|
摘要
目的:探究雷珠单抗在新生血管性青光眼治疗中的有效性与安全性。方法:选取2017年1月—2018年5月我院收治的60例新生血管性青光眼患者,根据治疗方法的不同分为实验组对照组,每组例数为30例。实验组给予雷珠单抗联合常规治疗,对照组仅给予常规治疗,观察两组患者眼压、术后并发症出现率、术后视力恢复情况。结果:实验组治疗后1周、1个月、3个月眼压低于对照组(28.25±1.25<40.69±1.87;21.97±1.58<30.36±1.88;16.97±1.27<25.41±1.39)mmHg;实验组治疗后视力小于0.1、0.1～0.2均小于对照组(6.67%<36.67%;13.33%<43.33%);视力大于0.2～0.6、大于0.6高于对照组(43.33%>16.67%;36.67%>33.33%);术后并发症总出现率小于对照组(10.00%<36.67%),组间差异值为P均<0.05。结论:在新生血管性青光眼治疗中加用雷珠单抗不仅有利于改善眼压,更利于改善视力,降低术后并发症出现率,具有独特的优势。
Objective: To investigate the efficacy and safety of Lei Zhu McAb in the treatment of neovascular glaucoma. Methods: From January 2017 to May 2018, 60 patients with neovascular glaucoma were divided into experimental group(n=30) and control group(n=30).The experimental group was given the combined routine therapy of Lei Zhu McAb and the control group was given the routine treatment.The IOP, the incidence of postoperative complications and the recovery of visual acuity were observed in the two groups. Results: The IOP in the experimental group was lower than that in the control group 1 week, 1 month and 3 months after treatment(28.25±1.25<40.69±1.87;21.97±1.58<30.36±1.88;16.97±1.27<25.41±1.39)mmHg; treatment, the visual acuity less than 0.1% was less than that in the control group(6.67%<36.67%<13.33%<43.33%). The visual acuity between 0.2～0.6,and above 0.6 was higher than that of the control group(43.33%>16.67%>36.67%>33.33%). The total incidence rate of postoperative complications was lower than that of control group(10.00% <36.67%),and the difference between groups was P<0.05. Conclusion: The application of Leizhu McAb in neovascular glaucoma treatment is not only bene?cial to improve intraocular pressure, but also to improve visual acuity and reduce the occurrence rate of postoperative complications. It has unique advantages and is worthy of further popularizing and applying in clinic.
Objective: To investigate the efficacy and safety of Lei Zhu McAb in the treatment of neovascular glaucoma. Methods: From January 2017 to May 2018, 60 patients with neovascular glaucoma were divided into experimental group(n=30) and control group(n=30).The experimental group was given the combined routine therapy of Lei Zhu McAb and the control group was given the routine treatment.The IOP, the incidence of postoperative complications and the recovery of visual acuity were observed in the two groups. Results: The IOP in the experimental group was lower than that in the control group 1 week, 1 month and 3 months after treatment(28.25±1.25<40.69±1.87;21.97±1.58<30.36±1.88;16.97±1.27<25.41±1.39)mmHg; treatment, the visual acuity less than 0.1% was less than that in the control group(6.67%<36.67%<13.33%<43.33%). The visual acuity between 0.2～0.6,and above 0.6 was higher than that of the control group(43.33%>16.67%>36.67%>33.33%). The total incidence rate of postoperative complications was lower than that of control group(10.00% <36.67%),and the difference between groups was P<0.05. Conclusion: The application of Leizhu McAb in neovascular glaucoma treatment is not only bene?cial to improve intraocular pressure, but also to improve visual acuity and reduce the occurrence rate of postoperative complications. It has unique advantages and is worthy of further popularizing and applying in clinic.
引文
[1]范志华,高雪霞,王瑞峰.玻璃体腔注射雷珠单抗联合小梁切除术治疗新生血管性青光眼[J].深圳中西医结合杂志, 2018, 28(21):94-95.
[2]邓月,张金莎.抗VEGF药物联合PRP治疗新生血管性青光眼的效果[J].国际眼科杂志, 2018, 18(10):1855-1858.
[3]赵雅楠,吴荷玉.玻璃体腔内注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的手术配合[J].全科护理, 2018, 16(27):3337-3339.
[4]林洁.贝伐单抗与雷珠单抗治疗新生血管性青光眼的对照研究[J].黑龙江医学, 2018, 42(06):532-536.
[5]林江,张强.玻璃体切除术中直视下睫状体光凝术联合雷珠单抗治疗新生血管性青光眼疗效观察[J].解放军预防医学杂志, 2018, 36(05):664-668.
[6]张晓利,毕明超,张佳宇,等.雷珠单抗玻璃体腔注射联合全视网膜光凝治疗新生血管性青光眼的疗效[J].中国老年学杂志, 2017, 37(08):2007-2008.
[7]周哲,胡佳丽,葛茸茸,等.玻璃体腔内注射雷珠单抗联合小梁切除术及视网膜光凝术治疗新生血管性青光眼[J].实用医学杂志, 2017, 33(02):249-252.
[8]党陈晔,龚政军.雷珠单抗治疗新生血管性眼病的临床疗效观察[J].实用医院临床杂志, 2016, 13(06):73-76.
[9]杨丽,唐慧.雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的临床观察[J].眼科新进展, 2016, 36(04):368-370.
[10]刘勇,平功勋.贝伐单抗与雷珠单抗联合Ahmed阀植入治疗NVG的对照研究[J].国际眼科杂志, 2015, 15(12):2114-2119.
[11]齐美华.玻璃体腔内注射雷珠单抗联合全视网膜激光光凝及小梁切除术治疗新生血管性青光眼的临床观察[J].内蒙古医学杂志,2015,47(12):1501-1503.
[12]王静.雷珠单抗在新生血管性青光眼治疗中的有效性与安全性分析[J].中国生化药物杂志, 2017, 37(11):421-422.
[2]邓月,张金莎.抗VEGF药物联合PRP治疗新生血管性青光眼的效果[J].国际眼科杂志, 2018, 18(10):1855-1858.
[3]赵雅楠,吴荷玉.玻璃体腔内注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的手术配合[J].全科护理, 2018, 16(27):3337-3339.
[4]林洁.贝伐单抗与雷珠单抗治疗新生血管性青光眼的对照研究[J].黑龙江医学, 2018, 42(06):532-536.
[5]林江,张强.玻璃体切除术中直视下睫状体光凝术联合雷珠单抗治疗新生血管性青光眼疗效观察[J].解放军预防医学杂志, 2018, 36(05):664-668.
[6]张晓利,毕明超,张佳宇,等.雷珠单抗玻璃体腔注射联合全视网膜光凝治疗新生血管性青光眼的疗效[J].中国老年学杂志, 2017, 37(08):2007-2008.
[7]周哲,胡佳丽,葛茸茸,等.玻璃体腔内注射雷珠单抗联合小梁切除术及视网膜光凝术治疗新生血管性青光眼[J].实用医学杂志, 2017, 33(02):249-252.
[8]党陈晔,龚政军.雷珠单抗治疗新生血管性眼病的临床疗效观察[J].实用医院临床杂志, 2016, 13(06):73-76.
[9]杨丽,唐慧.雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的临床观察[J].眼科新进展, 2016, 36(04):368-370.
[10]刘勇,平功勋.贝伐单抗与雷珠单抗联合Ahmed阀植入治疗NVG的对照研究[J].国际眼科杂志, 2015, 15(12):2114-2119.
[11]齐美华.玻璃体腔内注射雷珠单抗联合全视网膜激光光凝及小梁切除术治疗新生血管性青光眼的临床观察[J].内蒙古医学杂志,2015,47(12):1501-1503.
[12]王静.雷珠单抗在新生血管性青光眼治疗中的有效性与安全性分析[J].中国生化药物杂志, 2017, 37(11):421-422.